These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 37520573

  • 1. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis.
    Hu Y, Liu S, Wang L, Liu Y, Zhang D, Zhao Y.
    Front Immunol; 2023; 14():1202822. PubMed ID: 37520573
    [Abstract] [Full Text] [Related]

  • 2. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
    Tzeng A, Tzeng TH, Ornstein MC.
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599022
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Chen CY, Huang CH, Chen WC, Huang MS, Wei YF.
    Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
    [Abstract] [Full Text] [Related]

  • 9. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Matsumoto K, Shiroyama T, Kuge T, Miyake K, Yamamoto Y, Yoneda M, Yamamoto M, Naito Y, Suga Y, Fukushima K, Koyama S, Iwahori K, Hirata H, Nagatomo I, Takeda Y, Kumanogoh A.
    Lung Cancer; 2021 Dec; 162():175-184. PubMed ID: 34823108
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Discontinuation of Immune Checkpoint Inhibitor and Survival in Patients With Non-small-cell Lung Cancer Without a Driver Gene Mutation.
    Hattori S, Okauchi S, Sasatani Y, Ohara G, Miyazaki K, Sato S, Kodama T, Shiozawa T, Satoh H, Hizawa N.
    Anticancer Res; 2022 Sep; 42(9):4589-4595. PubMed ID: 36039463
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB, Dickhoff C, Schneiders FL, Senan S, Bahce I.
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study.
    Huang Z, Yan H, Zeng L, Xu Q, Guo W, Lin S, Jiang W, Wang Z, Deng L, Qin H, Zhang X, Tong F, Zhang R, Liu Z, Zhang L, Dong X, Yang N, Zhang Y.
    JCO Precis Oncol; 2023 Mar; 7():e2200614. PubMed ID: 36952645
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
    Sun S, Liu C, Duan C, Yu S, Zhang Q, Xu N, Yu B, Wu X, Wang J, Hu X, Yu H.
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):2937-2949. PubMed ID: 35835883
    [Abstract] [Full Text] [Related]

  • 19. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis.
    McKinley BJ, Pai TS, Wolf EB, Li S, Correia GSC, Zhao Y, Manochakian R, Lou Y.
    Front Oncol; 2024 Jul; 14():1417175. PubMed ID: 38974234
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB.
    Cancer; 2021 Mar 01; 127(5):709-719. PubMed ID: 33119177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.